nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—SRMS—kidney cancer	0.204	0.689	CbGaD
Dasatinib—KIT—kidney cancer	0.0553	0.187	CbGaD
Dasatinib—STK36—Pazopanib—kidney cancer	0.028	0.061	CbGbCtD
Dasatinib—LIMK2—Pazopanib—kidney cancer	0.028	0.061	CbGbCtD
Dasatinib—CYP1A1—kidney cancer	0.024	0.0811	CbGaD
Dasatinib—ZAK—Sorafenib—kidney cancer	0.0225	0.049	CbGbCtD
Dasatinib—BMPR1B—Pazopanib—kidney cancer	0.0223	0.0485	CbGbCtD
Dasatinib—MAP3K2—Pazopanib—kidney cancer	0.0161	0.035	CbGbCtD
Dasatinib—EPHB6—Pazopanib—kidney cancer	0.0142	0.031	CbGbCtD
Dasatinib—LYN—Pazopanib—kidney cancer	0.0142	0.031	CbGbCtD
Dasatinib—KIT—Pazopanib—kidney cancer	0.0128	0.0278	CbGbCtD
Dasatinib—PDGFRA—Pazopanib—kidney cancer	0.0128	0.0278	CbGbCtD
Dasatinib—CSF1R—Pazopanib—kidney cancer	0.0128	0.0278	CbGbCtD
Dasatinib—ABCB1—kidney cancer	0.0127	0.0431	CbGaD
Dasatinib—LCK—Pazopanib—kidney cancer	0.0116	0.0253	CbGbCtD
Dasatinib—MAP2K5—Pazopanib—kidney cancer	0.0116	0.0253	CbGbCtD
Dasatinib—PDGFRB—Pazopanib—kidney cancer	0.0116	0.0253	CbGbCtD
Dasatinib—MAP3K19—Pazopanib—kidney cancer	0.0107	0.0233	CbGbCtD
Dasatinib—JAK2—Sunitinib—kidney cancer	0.0105	0.0228	CbGbCtD
Dasatinib—FYN—Sunitinib—kidney cancer	0.0105	0.0228	CbGbCtD
Dasatinib—ABL2—Erlotinib—kidney cancer	0.00912	0.0199	CbGbCtD
Dasatinib—MAP4K5—Sunitinib—kidney cancer	0.00875	0.0191	CbGbCtD
Dasatinib—MAP3K3—Sunitinib—kidney cancer	0.00875	0.0191	CbGbCtD
Dasatinib—YES1—Sunitinib—kidney cancer	0.00875	0.0191	CbGbCtD
Dasatinib—MAP2K5—Erlotinib—kidney cancer	0.0083	0.0181	CbGbCtD
Dasatinib—EPHB6—Sorafenib—kidney cancer	0.00825	0.018	CbGbCtD
Dasatinib—MAP3K19—Erlotinib—kidney cancer	0.00763	0.0166	CbGbCtD
Dasatinib—MAP3K2—Sunitinib—kidney cancer	0.00756	0.0165	CbGbCtD
Dasatinib—FGR—Sunitinib—kidney cancer	0.00756	0.0165	CbGbCtD
Dasatinib—PDGFRA—Sorafenib—kidney cancer	0.00742	0.0161	CbGbCtD
Dasatinib—KIT—Sorafenib—kidney cancer	0.00742	0.0161	CbGbCtD
Dasatinib—CSF1R—Sorafenib—kidney cancer	0.00742	0.0161	CbGbCtD
Dasatinib—PDGFRB—Sorafenib—kidney cancer	0.00675	0.0147	CbGbCtD
Dasatinib—MAP2K5—Sorafenib—kidney cancer	0.00675	0.0147	CbGbCtD
Dasatinib—BLK—Sunitinib—kidney cancer	0.00669	0.0146	CbGbCtD
Dasatinib—EPHB6—Sunitinib—kidney cancer	0.00669	0.0146	CbGbCtD
Dasatinib—ABL1—Erlotinib—kidney cancer	0.00659	0.0144	CbGbCtD
Dasatinib—MAP3K19—Sorafenib—kidney cancer	0.0062	0.0135	CbGbCtD
Dasatinib—PDGFRA—Sunitinib—kidney cancer	0.00601	0.0131	CbGbCtD
Dasatinib—KIT—Sunitinib—kidney cancer	0.00601	0.0131	CbGbCtD
Dasatinib—CSF1R—Sunitinib—kidney cancer	0.00601	0.0131	CbGbCtD
Dasatinib—MAP2K5—Sunitinib—kidney cancer	0.00547	0.0119	CbGbCtD
Dasatinib—PDGFRB—Sunitinib—kidney cancer	0.00547	0.0119	CbGbCtD
Dasatinib—MAP3K19—Sunitinib—kidney cancer	0.00503	0.0109	CbGbCtD
Dasatinib—CYP1B1—Erlotinib—kidney cancer	0.00317	0.0069	CbGbCtD
Dasatinib—CYP1B1—Paclitaxel—kidney cancer	0.0029	0.00632	CbGbCtD
Dasatinib—CYP3A5—Temsirolimus—kidney cancer	0.00223	0.00485	CbGbCtD
Dasatinib—ABCG2—Pazopanib—kidney cancer	0.00211	0.0046	CbGbCtD
Dasatinib—ABCG2—Dactinomycin—kidney cancer	0.00193	0.0042	CbGbCtD
Dasatinib—CYP1B1—Doxorubicin—kidney cancer	0.00156	0.0034	CbGbCtD
Dasatinib—ABCG2—Erlotinib—kidney cancer	0.00151	0.00328	CbGbCtD
Dasatinib—ABCB1—Temsirolimus—kidney cancer	0.00145	0.00315	CbGbCtD
Dasatinib—CYP1A1—Erlotinib—kidney cancer	0.00139	0.00303	CbGbCtD
Dasatinib—ABCG2—Paclitaxel—kidney cancer	0.00138	0.003	CbGbCtD
Dasatinib—CYP3A4—Everolimus—kidney cancer	0.00129	0.0028	CbGbCtD
Dasatinib—FMO3—urine—kidney cancer	0.00124	0.0313	CbGeAlD
Dasatinib—ABCG2—Sorafenib—kidney cancer	0.00122	0.00267	CbGbCtD
Dasatinib—ABCG2—Vincristine—kidney cancer	0.00119	0.00259	CbGbCtD
Dasatinib—ABCG2—Sunitinib—kidney cancer	0.000992	0.00216	CbGbCtD
Dasatinib—CYP1A2—Pazopanib—kidney cancer	0.00087	0.0019	CbGbCtD
Dasatinib—CYP3A4—Temsirolimus—kidney cancer	0.000868	0.00189	CbGbCtD
Dasatinib—CYP3A5—Erlotinib—kidney cancer	0.000834	0.00182	CbGbCtD
Dasatinib—CYP3A5—Paclitaxel—kidney cancer	0.000764	0.00166	CbGbCtD
Dasatinib—ABCB1—Pazopanib—kidney cancer	0.000761	0.00166	CbGbCtD
Dasatinib—EPHB1—renal system—kidney cancer	0.000756	0.0191	CbGeAlD
Dasatinib—ABCG2—Doxorubicin—kidney cancer	0.000743	0.00162	CbGbCtD
Dasatinib—EPHB1—kidney—kidney cancer	0.000731	0.0185	CbGeAlD
Dasatinib—ABCB1—Dactinomycin—kidney cancer	0.000696	0.00152	CbGbCtD
Dasatinib—CYP3A5—Sorafenib—kidney cancer	0.000678	0.00148	CbGbCtD
Dasatinib—SIK2—renal system—kidney cancer	0.000668	0.0169	CbGeAlD
Dasatinib—CYP3A5—Vincristine—kidney cancer	0.000659	0.00143	CbGbCtD
Dasatinib—FRK—renal system—kidney cancer	0.000651	0.0164	CbGeAlD
Dasatinib—CYP1A2—Erlotinib—kidney cancer	0.000621	0.00135	CbGbCtD
Dasatinib—SRMS—renal system—kidney cancer	0.000607	0.0153	CbGeAlD
Dasatinib—PTK6—renal system—kidney cancer	0.000595	0.015	CbGeAlD
Dasatinib—SRMS—kidney—kidney cancer	0.000587	0.0148	CbGeAlD
Dasatinib—PKMYT1—gonad—kidney cancer	0.000583	0.0147	CbGeAlD
Dasatinib—FRK—gonad—kidney cancer	0.000583	0.0147	CbGeAlD
Dasatinib—STAT5B—renal system—kidney cancer	0.000563	0.0142	CbGeAlD
Dasatinib—SIK3—nephron tubule—kidney cancer	0.000557	0.0141	CbGeAlD
Dasatinib—ABCB1—Gemcitabine—kidney cancer	0.00055	0.0012	CbGbCtD
Dasatinib—CYP3A5—Sunitinib—kidney cancer	0.00055	0.0012	CbGbCtD
Dasatinib—STAT5B—kidney—kidney cancer	0.000544	0.0137	CbGeAlD
Dasatinib—ABCB1—Erlotinib—kidney cancer	0.000543	0.00118	CbGbCtD
Dasatinib—CYP1A2—Sorafenib—kidney cancer	0.000505	0.0011	CbGbCtD
Dasatinib—STAT5B—gonad—kidney cancer	0.000505	0.0127	CbGeAlD
Dasatinib—ABCB1—Paclitaxel—kidney cancer	0.000497	0.00108	CbGbCtD
Dasatinib—SIK3—cortex of kidney—kidney cancer	0.000476	0.012	CbGeAlD
Dasatinib—TESK1—nephron tubule—kidney cancer	0.000457	0.0116	CbGeAlD
Dasatinib—CYP3A4—Pazopanib—kidney cancer	0.000456	0.000993	CbGbCtD
Dasatinib—SIK3—gonad—kidney cancer	0.000454	0.0115	CbGeAlD
Dasatinib—SIK3—cardiac atrium—kidney cancer	0.000453	0.0114	CbGeAlD
Dasatinib—CYP1A2—urine—kidney cancer	0.000447	0.0113	CbGeAlD
Dasatinib—ABCB1—Sorafenib—kidney cancer	0.000442	0.000962	CbGbCtD
Dasatinib—ABCB1—Vinblastine—kidney cancer	0.000436	0.000949	CbGbCtD
Dasatinib—ABCB1—Vincristine—kidney cancer	0.000429	0.000933	CbGbCtD
Dasatinib—CSK—nephron tubule—kidney cancer	0.000419	0.0106	CbGeAlD
Dasatinib—TESK1—renal system—kidney cancer	0.000416	0.0105	CbGeAlD
Dasatinib—TESK1—cortex of kidney—kidney cancer	0.000392	0.00989	CbGeAlD
Dasatinib—RIPK2—nephron tubule—kidney cancer	0.000389	0.00983	CbGeAlD
Dasatinib—STK36—cortex of kidney—kidney cancer	0.000385	0.00973	CbGeAlD
Dasatinib—CSK—renal system—kidney cancer	0.000381	0.00962	CbGeAlD
Dasatinib—SIK1—nephron tubule—kidney cancer	0.00038	0.0096	CbGeAlD
Dasatinib—TESK1—gonad—kidney cancer	0.000373	0.00942	CbGeAlD
Dasatinib—LIMK2—cortex of kidney—kidney cancer	0.000372	0.00941	CbGeAlD
Dasatinib—TESK1—cardiac atrium—kidney cancer	0.000372	0.00941	CbGeAlD
Dasatinib—ERBB3—nephron tubule—kidney cancer	0.000372	0.00941	CbGeAlD
Dasatinib—MAP3K2—nephron tubule—kidney cancer	0.000369	0.00932	CbGeAlD
Dasatinib—CSK—kidney—kidney cancer	0.000368	0.0093	CbGeAlD
Dasatinib—STK36—gonad—kidney cancer	0.000367	0.00927	CbGeAlD
Dasatinib—CSK—cortex of kidney—kidney cancer	0.000359	0.00906	CbGeAlD
Dasatinib—ABCB1—Sunitinib—kidney cancer	0.000358	0.000779	CbGbCtD
Dasatinib—LIMK2—gonad—kidney cancer	0.000355	0.00896	CbGeAlD
Dasatinib—SIK1—renal system—kidney cancer	0.000345	0.00872	CbGeAlD
Dasatinib—STK35—gonad—kidney cancer	0.000344	0.00869	CbGeAlD
Dasatinib—STK35—cardiac atrium—kidney cancer	0.000343	0.00868	CbGeAlD
Dasatinib—CSK—gonad—kidney cancer	0.000342	0.00863	CbGeAlD
Dasatinib—CSK—cardiac atrium—kidney cancer	0.000341	0.00862	CbGeAlD
Dasatinib—ERBB3—renal system—kidney cancer	0.000338	0.00855	CbGeAlD
Dasatinib—SIK1—kidney—kidney cancer	0.000334	0.00843	CbGeAlD
Dasatinib—EPHB4—nephron tubule—kidney cancer	0.000329	0.0083	CbGeAlD
Dasatinib—ERBB3—kidney—kidney cancer	0.000327	0.00827	CbGeAlD
Dasatinib—CYP3A4—Erlotinib—kidney cancer	0.000325	0.000709	CbGbCtD
Dasatinib—SIK1—cortex of kidney—kidney cancer	0.000325	0.00821	CbGeAlD
Dasatinib—CYP3A4—urine—kidney cancer	0.000324	0.00818	CbGeAlD
Dasatinib—EPHA2—nephron tubule—kidney cancer	0.000322	0.00815	CbGeAlD
Dasatinib—FYN—nephron tubule—kidney cancer	0.000322	0.00813	CbGeAlD
Dasatinib—RIPK2—cardiac atrium—kidney cancer	0.000317	0.008	CbGeAlD
Dasatinib—MAPK14—renal system—kidney cancer	0.000315	0.00796	CbGeAlD
Dasatinib—MAP3K3—nephron tubule—kidney cancer	0.000315	0.00795	CbGeAlD
Dasatinib—SIK1—gonad—kidney cancer	0.00031	0.00782	CbGeAlD
Dasatinib—SIK1—cardiac atrium—kidney cancer	0.000309	0.00781	CbGeAlD
Dasatinib—EPHA4—gonad—kidney cancer	0.000306	0.00774	CbGeAlD
Dasatinib—EPHA4—cardiac atrium—kidney cancer	0.000306	0.00773	CbGeAlD
Dasatinib—MAPK14—kidney—kidney cancer	0.000305	0.0077	CbGeAlD
Dasatinib—MAP3K2—gonad—kidney cancer	0.000301	0.00759	CbGeAlD
Dasatinib—EPHB4—renal system—kidney cancer	0.000299	0.00755	CbGeAlD
Dasatinib—CYP3A4—Paclitaxel—kidney cancer	0.000298	0.000649	CbGbCtD
Dasatinib—JAK2—renal system—kidney cancer	0.000297	0.00749	CbGeAlD
Dasatinib—FYN—renal system—kidney cancer	0.000293	0.00739	CbGeAlD
Dasatinib—YES1—nephron tubule—kidney cancer	0.00029	0.00734	CbGeAlD
Dasatinib—EPHB4—kidney—kidney cancer	0.000289	0.0073	CbGeAlD
Dasatinib—JAK2—kidney—kidney cancer	0.000287	0.00725	CbGeAlD
Dasatinib—FYN—kidney—kidney cancer	0.000283	0.00715	CbGeAlD
Dasatinib—EPHB4—cortex of kidney—kidney cancer	0.000281	0.00711	CbGeAlD
Dasatinib—JAK2—cortex of kidney—kidney cancer	0.000279	0.00706	CbGeAlD
Dasatinib—CSK—Sirolimus—Temsirolimus—kidney cancer	0.000279	0.172	CbGdCrCtD
Dasatinib—CSK—Sirolimus—Everolimus—kidney cancer	0.000279	0.172	CbGdCrCtD
Dasatinib—CSK—Everolimus—Temsirolimus—kidney cancer	0.000279	0.172	CbGdCrCtD
Dasatinib—CSK—Temsirolimus—Everolimus—kidney cancer	0.000279	0.172	CbGdCrCtD
Dasatinib—FYN—cortex of kidney—kidney cancer	0.000275	0.00696	CbGeAlD
Dasatinib—MAP4K5—cortex of kidney—kidney cancer	0.000269	0.0068	CbGeAlD
Dasatinib—MAP3K3—cortex of kidney—kidney cancer	0.000269	0.0068	CbGeAlD
Dasatinib—ABCB1—Doxorubicin—kidney cancer	0.000268	0.000583	CbGbCtD
Dasatinib—EPHB4—cardiac atrium—kidney cancer	0.000268	0.00676	CbGeAlD
Dasatinib—JAK2—gonad—kidney cancer	0.000266	0.00672	CbGeAlD
Dasatinib—JAK2—cardiac atrium—kidney cancer	0.000266	0.00671	CbGeAlD
Dasatinib—CYP3A4—Sorafenib—kidney cancer	0.000265	0.000576	CbGbCtD
Dasatinib—YES1—renal system—kidney cancer	0.000264	0.00667	CbGeAlD
Dasatinib—EPHA2—cardiac atrium—kidney cancer	0.000262	0.00663	CbGeAlD
Dasatinib—FYN—cardiac atrium—kidney cancer	0.000262	0.00662	CbGeAlD
Dasatinib—CYP3A4—Vinblastine—kidney cancer	0.000261	0.000569	CbGbCtD
Dasatinib—PDGFRA—renal system—kidney cancer	0.000259	0.00654	CbGeAlD
Dasatinib—EPHB6—cortex of kidney—kidney cancer	0.000257	0.0065	CbGeAlD
Dasatinib—CYP3A4—Vincristine—kidney cancer	0.000257	0.000559	CbGbCtD
Dasatinib—MAP3K3—gonad—kidney cancer	0.000256	0.00648	CbGeAlD
Dasatinib—MAP4K5—gonad—kidney cancer	0.000256	0.00648	CbGeAlD
Dasatinib—MAP3K3—cardiac atrium—kidney cancer	0.000256	0.00647	CbGeAlD
Dasatinib—MAP4K5—cardiac atrium—kidney cancer	0.000256	0.00647	CbGeAlD
Dasatinib—YES1—kidney—kidney cancer	0.000255	0.00645	CbGeAlD
Dasatinib—SRC—renal system—kidney cancer	0.000254	0.00642	CbGeAlD
Dasatinib—YES1—cortex of kidney—kidney cancer	0.000249	0.00628	CbGeAlD
Dasatinib—SRC—kidney—kidney cancer	0.000246	0.0062	CbGeAlD
Dasatinib—EPHB6—cardiac atrium—kidney cancer	0.000245	0.00618	CbGeAlD
Dasatinib—YES1—gonad—kidney cancer	0.000237	0.00598	CbGeAlD
Dasatinib—YES1—cardiac atrium—kidney cancer	0.000236	0.00597	CbGeAlD
Dasatinib—PDGFRA—gonad—kidney cancer	0.000232	0.00587	CbGeAlD
Dasatinib—KIT—nephron tubule—kidney cancer	0.000228	0.00576	CbGeAlD
Dasatinib—SRC—gonad—kidney cancer	0.000228	0.00576	CbGeAlD
Dasatinib—SRC—cardiac atrium—kidney cancer	0.000227	0.00575	CbGeAlD
Dasatinib—MAP2K5—cortex of kidney—kidney cancer	0.00022	0.00556	CbGeAlD
Dasatinib—CYP3A4—Sunitinib—kidney cancer	0.000214	0.000467	CbGbCtD
Dasatinib—MAP2K5—cardiac atrium—kidney cancer	0.000209	0.00529	CbGeAlD
Dasatinib—KIT—renal system—kidney cancer	0.000207	0.00523	CbGeAlD
Dasatinib—CSF1R—gonad—kidney cancer	0.000204	0.00517	CbGeAlD
Dasatinib—CSF1R—cardiac atrium—kidney cancer	0.000204	0.00516	CbGeAlD
Dasatinib—PDGFRB—renal system—kidney cancer	0.000202	0.00511	CbGeAlD
Dasatinib—KIT—kidney—kidney cancer	0.0002	0.00506	CbGeAlD
Dasatinib—ABL1—nephron tubule—kidney cancer	0.000198	0.00501	CbGeAlD
Dasatinib—PDGFRB—kidney—kidney cancer	0.000196	0.00494	CbGeAlD
Dasatinib—KIT—cortex of kidney—kidney cancer	0.000195	0.00493	CbGeAlD
Dasatinib—PDGFRB—cortex of kidney—kidney cancer	0.00019	0.00481	CbGeAlD
Dasatinib—KIT—gonad—kidney cancer	0.000186	0.00469	CbGeAlD
Dasatinib—PDGFRB—gonad—kidney cancer	0.000181	0.00458	CbGeAlD
Dasatinib—PDGFRB—cardiac atrium—kidney cancer	0.000181	0.00458	CbGeAlD
Dasatinib—ABL1—renal system—kidney cancer	0.00018	0.00455	CbGeAlD
Dasatinib—ABL1—kidney—kidney cancer	0.000174	0.0044	CbGeAlD
Dasatinib—ABL1—cortex of kidney—kidney cancer	0.00017	0.00429	CbGeAlD
Dasatinib—CYP1B1—nephron tubule—kidney cancer	0.000168	0.00424	CbGeAlD
Dasatinib—ABL1—gonad—kidney cancer	0.000162	0.00408	CbGeAlD
Dasatinib—ABL1—cardiac atrium—kidney cancer	0.000161	0.00408	CbGeAlD
Dasatinib—CYP3A4—Doxorubicin—kidney cancer	0.000161	0.00035	CbGbCtD
Dasatinib—CYP1B1—renal system—kidney cancer	0.000153	0.00386	CbGeAlD
Dasatinib—CYP1B1—kidney—kidney cancer	0.000148	0.00373	CbGeAlD
Dasatinib—CYP1B1—cortex of kidney—kidney cancer	0.000144	0.00363	CbGeAlD
Dasatinib—ERBB3—Vinblastine—Vincristine—kidney cancer	0.000139	0.0856	CbGdCrCtD
Dasatinib—CYP1B1—gonad—kidney cancer	0.000137	0.00346	CbGeAlD
Dasatinib—ABCG2—nephron tubule—kidney cancer	0.000125	0.00316	CbGeAlD
Dasatinib—CYP3A5—nephron tubule—kidney cancer	0.000116	0.00293	CbGeAlD
Dasatinib—CYP1A2—renal system—kidney cancer	0.000109	0.00276	CbGeAlD
Dasatinib—CYP1A1—renal system—kidney cancer	0.000108	0.00273	CbGeAlD
Dasatinib—CYP3A5—renal system—kidney cancer	0.000106	0.00267	CbGeAlD
Dasatinib—CYP1A1—kidney—kidney cancer	0.000104	0.00264	CbGeAlD
Dasatinib—CYP3A5—kidney—kidney cancer	0.000102	0.00258	CbGeAlD
Dasatinib—CYP3A5—cortex of kidney—kidney cancer	9.93e-05	0.00251	CbGeAlD
Dasatinib—CYP1A1—cardiac atrium—kidney cancer	9.66e-05	0.00244	CbGeAlD
Dasatinib—CSK—Daunorubicin—Doxorubicin—kidney cancer	8.99e-05	0.0554	CbGdCrCtD
Dasatinib—CSK—Epirubicin—Doxorubicin—kidney cancer	8.99e-05	0.0554	CbGdCrCtD
Dasatinib—CYP3A4—renal system—kidney cancer	7.92e-05	0.002	CbGeAlD
Dasatinib—CYP3A4—kidney—kidney cancer	7.66e-05	0.00193	CbGeAlD
Dasatinib—ABL1—Epirubicin—Doxorubicin—kidney cancer	6.28e-05	0.0387	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Doxorubicin—kidney cancer	6.28e-05	0.0387	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Doxorubicin—kidney cancer	6.28e-05	0.0387	CbGdCrCtD
Dasatinib—ABCB1—nephron tubule—kidney cancer	6.17e-05	0.00156	CbGeAlD
Dasatinib—ABCB1—renal system—kidney cancer	5.61e-05	0.00142	CbGeAlD
Dasatinib—ABCB1—kidney—kidney cancer	5.42e-05	0.00137	CbGeAlD
Dasatinib—ABCB1—cortex of kidney—kidney cancer	5.28e-05	0.00133	CbGeAlD
Dasatinib—ABCB1—gonad—kidney cancer	5.03e-05	0.00127	CbGeAlD
Dasatinib—Chills—Capecitabine—kidney cancer	2.24e-05	0.000208	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	2.24e-05	0.000208	CcSEcCtD
Dasatinib—Arrhythmia—Capecitabine—kidney cancer	2.23e-05	0.000207	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Gemcitabine—kidney cancer	2.23e-05	0.000207	CcSEcCtD
Dasatinib—Discomfort—Paclitaxel—kidney cancer	2.23e-05	0.000207	CcSEcCtD
Dasatinib—Fatigue—Gemcitabine—kidney cancer	2.22e-05	0.000207	CcSEcCtD
Dasatinib—Gastrointestinal pain—Vincristine—kidney cancer	2.22e-05	0.000207	CcSEcCtD
Dasatinib—Dizziness—Sorafenib—kidney cancer	2.21e-05	0.000206	CcSEcCtD
Dasatinib—Constipation—Gemcitabine—kidney cancer	2.21e-05	0.000205	CcSEcCtD
Dasatinib—Pain—Gemcitabine—kidney cancer	2.21e-05	0.000205	CcSEcCtD
Dasatinib—Nausea—Erlotinib—kidney cancer	2.21e-05	0.000205	CcSEcCtD
Dasatinib—Alopecia—Capecitabine—kidney cancer	2.2e-05	0.000205	CcSEcCtD
Dasatinib—Diarrhoea—Sunitinib—kidney cancer	2.2e-05	0.000205	CcSEcCtD
Dasatinib—Mental disorder—Capecitabine—kidney cancer	2.19e-05	0.000203	CcSEcCtD
Dasatinib—Asthenia—Dactinomycin—kidney cancer	2.18e-05	0.000203	CcSEcCtD
Dasatinib—Confusional state—Paclitaxel—kidney cancer	2.18e-05	0.000203	CcSEcCtD
Dasatinib—Blood creatinine increased—Doxorubicin—kidney cancer	2.18e-05	0.000203	CcSEcCtD
Dasatinib—Malnutrition—Capecitabine—kidney cancer	2.17e-05	0.000202	CcSEcCtD
Dasatinib—Erythema—Capecitabine—kidney cancer	2.17e-05	0.000202	CcSEcCtD
Dasatinib—Oedema—Paclitaxel—kidney cancer	2.16e-05	0.000201	CcSEcCtD
Dasatinib—Body temperature increased—Vincristine—kidney cancer	2.15e-05	0.0002	CcSEcCtD
Dasatinib—Abdominal pain—Vincristine—kidney cancer	2.15e-05	0.0002	CcSEcCtD
Dasatinib—Infection—Paclitaxel—kidney cancer	2.15e-05	0.0002	CcSEcCtD
Dasatinib—Dry skin—Doxorubicin—kidney cancer	2.13e-05	0.000198	CcSEcCtD
Dasatinib—Dysgeusia—Capecitabine—kidney cancer	2.13e-05	0.000198	CcSEcCtD
Dasatinib—Dizziness—Sunitinib—kidney cancer	2.13e-05	0.000198	CcSEcCtD
Dasatinib—Feeling abnormal—Gemcitabine—kidney cancer	2.13e-05	0.000198	CcSEcCtD
Dasatinib—Shock—Paclitaxel—kidney cancer	2.12e-05	0.000198	CcSEcCtD
Dasatinib—Vomiting—Sorafenib—kidney cancer	2.12e-05	0.000198	CcSEcCtD
Dasatinib—Nervous system disorder—Paclitaxel—kidney cancer	2.12e-05	0.000197	CcSEcCtD
Dasatinib—Hypokalaemia—Doxorubicin—kidney cancer	2.12e-05	0.000197	CcSEcCtD
Dasatinib—Thrombocytopenia—Paclitaxel—kidney cancer	2.11e-05	0.000197	CcSEcCtD
Dasatinib—Tachycardia—Paclitaxel—kidney cancer	2.11e-05	0.000196	CcSEcCtD
Dasatinib—Rash—Sorafenib—kidney cancer	2.11e-05	0.000196	CcSEcCtD
Dasatinib—Dermatitis—Sorafenib—kidney cancer	2.1e-05	0.000196	CcSEcCtD
Dasatinib—Breast disorder—Doxorubicin—kidney cancer	2.1e-05	0.000195	CcSEcCtD
Dasatinib—Skin disorder—Paclitaxel—kidney cancer	2.1e-05	0.000195	CcSEcCtD
Dasatinib—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	2.09e-05	0.000195	CcSEcCtD
Dasatinib—Headache—Sorafenib—kidney cancer	2.09e-05	0.000195	CcSEcCtD
Dasatinib—Muscle spasms—Capecitabine—kidney cancer	2.09e-05	0.000194	CcSEcCtD
Dasatinib—Hyperhidrosis—Paclitaxel—kidney cancer	2.09e-05	0.000194	CcSEcCtD
Dasatinib—Diarrhoea—Dactinomycin—kidney cancer	2.08e-05	0.000194	CcSEcCtD
Dasatinib—Anorexia—Paclitaxel—kidney cancer	2.06e-05	0.000192	CcSEcCtD
Dasatinib—Gastritis—Doxorubicin—kidney cancer	2.06e-05	0.000191	CcSEcCtD
Dasatinib—Alanine aminotransferase increased—Doxorubicin—kidney cancer	2.05e-05	0.000191	CcSEcCtD
Dasatinib—Muscular weakness—Doxorubicin—kidney cancer	2.05e-05	0.000191	CcSEcCtD
Dasatinib—Vision blurred—Capecitabine—kidney cancer	2.05e-05	0.00019	CcSEcCtD
Dasatinib—Vomiting—Sunitinib—kidney cancer	2.04e-05	0.00019	CcSEcCtD
Dasatinib—Body temperature increased—Gemcitabine—kidney cancer	2.04e-05	0.00019	CcSEcCtD
Dasatinib—Tremor—Capecitabine—kidney cancer	2.03e-05	0.000189	CcSEcCtD
Dasatinib—Rash—Sunitinib—kidney cancer	2.03e-05	0.000189	CcSEcCtD
Dasatinib—Dermatitis—Sunitinib—kidney cancer	2.02e-05	0.000188	CcSEcCtD
Dasatinib—Abdominal distension—Doxorubicin—kidney cancer	2.02e-05	0.000188	CcSEcCtD
Dasatinib—Hypotension—Paclitaxel—kidney cancer	2.02e-05	0.000188	CcSEcCtD
Dasatinib—Ill-defined disorder—Capecitabine—kidney cancer	2.01e-05	0.000187	CcSEcCtD
Dasatinib—Headache—Sunitinib—kidney cancer	2.01e-05	0.000187	CcSEcCtD
Dasatinib—Dysphagia—Doxorubicin—kidney cancer	2.01e-05	0.000187	CcSEcCtD
Dasatinib—Asthma—Doxorubicin—kidney cancer	2.01e-05	0.000187	CcSEcCtD
Dasatinib—Anaemia—Capecitabine—kidney cancer	2.01e-05	0.000187	CcSEcCtD
Dasatinib—Hypersensitivity—Vincristine—kidney cancer	2e-05	0.000186	CcSEcCtD
Dasatinib—Nausea—Sorafenib—kidney cancer	1.98e-05	0.000185	CcSEcCtD
Dasatinib—Pancreatitis—Doxorubicin—kidney cancer	1.97e-05	0.000183	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Paclitaxel—kidney cancer	1.97e-05	0.000183	CcSEcCtD
Dasatinib—Malaise—Capecitabine—kidney cancer	1.96e-05	0.000182	CcSEcCtD
Dasatinib—Angina pectoris—Doxorubicin—kidney cancer	1.96e-05	0.000182	CcSEcCtD
Dasatinib—Insomnia—Paclitaxel—kidney cancer	1.95e-05	0.000182	CcSEcCtD
Dasatinib—Vertigo—Capecitabine—kidney cancer	1.95e-05	0.000182	CcSEcCtD
Dasatinib—Asthenia—Vincristine—kidney cancer	1.95e-05	0.000181	CcSEcCtD
Dasatinib—Syncope—Capecitabine—kidney cancer	1.95e-05	0.000181	CcSEcCtD
Dasatinib—Vomiting—Dactinomycin—kidney cancer	1.93e-05	0.00018	CcSEcCtD
Dasatinib—Dyspnoea—Paclitaxel—kidney cancer	1.93e-05	0.000179	CcSEcCtD
Dasatinib—Somnolence—Paclitaxel—kidney cancer	1.92e-05	0.000179	CcSEcCtD
Dasatinib—Palpitations—Capecitabine—kidney cancer	1.92e-05	0.000179	CcSEcCtD
Dasatinib—Rash—Dactinomycin—kidney cancer	1.92e-05	0.000179	CcSEcCtD
Dasatinib—Nausea—Sunitinib—kidney cancer	1.91e-05	0.000178	CcSEcCtD
Dasatinib—Loss of consciousness—Capecitabine—kidney cancer	1.91e-05	0.000178	CcSEcCtD
Dasatinib—Pancytopenia—Doxorubicin—kidney cancer	1.91e-05	0.000177	CcSEcCtD
Dasatinib—Dyspepsia—Paclitaxel—kidney cancer	1.9e-05	0.000177	CcSEcCtD
Dasatinib—Cough—Capecitabine—kidney cancer	1.89e-05	0.000176	CcSEcCtD
Dasatinib—Neutropenia—Doxorubicin—kidney cancer	1.88e-05	0.000175	CcSEcCtD
Dasatinib—Decreased appetite—Paclitaxel—kidney cancer	1.88e-05	0.000175	CcSEcCtD
Dasatinib—Hypertension—Capecitabine—kidney cancer	1.87e-05	0.000174	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Doxorubicin—kidney cancer	1.87e-05	0.000174	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Paclitaxel—kidney cancer	1.86e-05	0.000173	CcSEcCtD
Dasatinib—Fatigue—Paclitaxel—kidney cancer	1.86e-05	0.000173	CcSEcCtD
Dasatinib—Diarrhoea—Vincristine—kidney cancer	1.86e-05	0.000173	CcSEcCtD
Dasatinib—Pollakiuria—Doxorubicin—kidney cancer	1.86e-05	0.000173	CcSEcCtD
Dasatinib—Asthenia—Gemcitabine—kidney cancer	1.85e-05	0.000172	CcSEcCtD
Dasatinib—Arthralgia—Capecitabine—kidney cancer	1.85e-05	0.000172	CcSEcCtD
Dasatinib—Myalgia—Capecitabine—kidney cancer	1.85e-05	0.000172	CcSEcCtD
Dasatinib—Chest pain—Capecitabine—kidney cancer	1.85e-05	0.000172	CcSEcCtD
Dasatinib—Constipation—Paclitaxel—kidney cancer	1.85e-05	0.000172	CcSEcCtD
Dasatinib—Pain—Paclitaxel—kidney cancer	1.85e-05	0.000172	CcSEcCtD
Dasatinib—Anxiety—Capecitabine—kidney cancer	1.84e-05	0.000171	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	1.84e-05	0.000171	CcSEcCtD
Dasatinib—Photosensitivity reaction—Doxorubicin—kidney cancer	1.83e-05	0.000171	CcSEcCtD
Dasatinib—Weight increased—Doxorubicin—kidney cancer	1.83e-05	0.00017	CcSEcCtD
Dasatinib—Discomfort—Capecitabine—kidney cancer	1.83e-05	0.00017	CcSEcCtD
Dasatinib—Pruritus—Gemcitabine—kidney cancer	1.82e-05	0.00017	CcSEcCtD
Dasatinib—Weight decreased—Doxorubicin—kidney cancer	1.82e-05	0.000169	CcSEcCtD
Dasatinib—Nausea—Dactinomycin—kidney cancer	1.81e-05	0.000168	CcSEcCtD
Dasatinib—Pneumonia—Doxorubicin—kidney cancer	1.8e-05	0.000168	CcSEcCtD
Dasatinib—Dizziness—Vincristine—kidney cancer	1.8e-05	0.000167	CcSEcCtD
Dasatinib—Infestation NOS—Doxorubicin—kidney cancer	1.79e-05	0.000167	CcSEcCtD
Dasatinib—Infestation—Doxorubicin—kidney cancer	1.79e-05	0.000167	CcSEcCtD
Dasatinib—Confusional state—Capecitabine—kidney cancer	1.79e-05	0.000166	CcSEcCtD
Dasatinib—Feeling abnormal—Paclitaxel—kidney cancer	1.78e-05	0.000166	CcSEcCtD
Dasatinib—Oedema—Capecitabine—kidney cancer	1.77e-05	0.000165	CcSEcCtD
Dasatinib—Gastrointestinal pain—Paclitaxel—kidney cancer	1.77e-05	0.000164	CcSEcCtD
Dasatinib—Diarrhoea—Gemcitabine—kidney cancer	1.76e-05	0.000164	CcSEcCtD
Dasatinib—Renal failure—Doxorubicin—kidney cancer	1.76e-05	0.000164	CcSEcCtD
Dasatinib—Infection—Capecitabine—kidney cancer	1.76e-05	0.000164	CcSEcCtD
Dasatinib—Neuropathy peripheral—Doxorubicin—kidney cancer	1.76e-05	0.000163	CcSEcCtD
Dasatinib—Stomatitis—Doxorubicin—kidney cancer	1.75e-05	0.000162	CcSEcCtD
Dasatinib—Shock—Capecitabine—kidney cancer	1.74e-05	0.000162	CcSEcCtD
Dasatinib—Conjunctivitis—Doxorubicin—kidney cancer	1.74e-05	0.000162	CcSEcCtD
Dasatinib—Nervous system disorder—Capecitabine—kidney cancer	1.74e-05	0.000162	CcSEcCtD
Dasatinib—Thrombocytopenia—Capecitabine—kidney cancer	1.74e-05	0.000161	CcSEcCtD
Dasatinib—Tachycardia—Capecitabine—kidney cancer	1.73e-05	0.000161	CcSEcCtD
Dasatinib—Vomiting—Vincristine—kidney cancer	1.73e-05	0.000161	CcSEcCtD
Dasatinib—Skin disorder—Capecitabine—kidney cancer	1.72e-05	0.00016	CcSEcCtD
Dasatinib—Urticaria—Paclitaxel—kidney cancer	1.72e-05	0.00016	CcSEcCtD
Dasatinib—Rash—Vincristine—kidney cancer	1.71e-05	0.000159	CcSEcCtD
Dasatinib—Hyperhidrosis—Capecitabine—kidney cancer	1.71e-05	0.000159	CcSEcCtD
Dasatinib—Dermatitis—Vincristine—kidney cancer	1.71e-05	0.000159	CcSEcCtD
Dasatinib—Haematuria—Doxorubicin—kidney cancer	1.71e-05	0.000159	CcSEcCtD
Dasatinib—Abdominal pain—Paclitaxel—kidney cancer	1.71e-05	0.000159	CcSEcCtD
Dasatinib—Body temperature increased—Paclitaxel—kidney cancer	1.71e-05	0.000159	CcSEcCtD
Dasatinib—Headache—Vincristine—kidney cancer	1.7e-05	0.000158	CcSEcCtD
Dasatinib—Hepatobiliary disease—Doxorubicin—kidney cancer	1.69e-05	0.000158	CcSEcCtD
Dasatinib—Epistaxis—Doxorubicin—kidney cancer	1.69e-05	0.000157	CcSEcCtD
Dasatinib—Anorexia—Capecitabine—kidney cancer	1.69e-05	0.000157	CcSEcCtD
Dasatinib—Hypotension—Capecitabine—kidney cancer	1.66e-05	0.000154	CcSEcCtD
Dasatinib—Vomiting—Gemcitabine—kidney cancer	1.64e-05	0.000153	CcSEcCtD
Dasatinib—Rash—Gemcitabine—kidney cancer	1.63e-05	0.000151	CcSEcCtD
Dasatinib—Dermatitis—Gemcitabine—kidney cancer	1.62e-05	0.000151	CcSEcCtD
Dasatinib—Haemoglobin—Doxorubicin—kidney cancer	1.62e-05	0.00015	CcSEcCtD
Dasatinib—Headache—Gemcitabine—kidney cancer	1.62e-05	0.00015	CcSEcCtD
Dasatinib—Nausea—Vincristine—kidney cancer	1.61e-05	0.00015	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Capecitabine—kidney cancer	1.61e-05	0.00015	CcSEcCtD
Dasatinib—Hepatitis—Doxorubicin—kidney cancer	1.61e-05	0.00015	CcSEcCtD
Dasatinib—Haemorrhage—Doxorubicin—kidney cancer	1.61e-05	0.00015	CcSEcCtD
Dasatinib—Insomnia—Capecitabine—kidney cancer	1.6e-05	0.000149	CcSEcCtD
Dasatinib—Hypersensitivity—Paclitaxel—kidney cancer	1.59e-05	0.000148	CcSEcCtD
Dasatinib—Urinary tract disorder—Doxorubicin—kidney cancer	1.59e-05	0.000148	CcSEcCtD
Dasatinib—Oedema peripheral—Doxorubicin—kidney cancer	1.58e-05	0.000147	CcSEcCtD
Dasatinib—Connective tissue disorder—Doxorubicin—kidney cancer	1.58e-05	0.000147	CcSEcCtD
Dasatinib—Dyspnoea—Capecitabine—kidney cancer	1.58e-05	0.000147	CcSEcCtD
Dasatinib—Urethral disorder—Doxorubicin—kidney cancer	1.58e-05	0.000147	CcSEcCtD
Dasatinib—Dyspepsia—Capecitabine—kidney cancer	1.56e-05	0.000145	CcSEcCtD
Dasatinib—Visual impairment—Doxorubicin—kidney cancer	1.55e-05	0.000144	CcSEcCtD
Dasatinib—Asthenia—Paclitaxel—kidney cancer	1.55e-05	0.000144	CcSEcCtD
Dasatinib—Decreased appetite—Capecitabine—kidney cancer	1.54e-05	0.000143	CcSEcCtD
Dasatinib—Nausea—Gemcitabine—kidney cancer	1.53e-05	0.000143	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Capecitabine—kidney cancer	1.53e-05	0.000142	CcSEcCtD
Dasatinib—Fatigue—Capecitabine—kidney cancer	1.53e-05	0.000142	CcSEcCtD
Dasatinib—Pruritus—Paclitaxel—kidney cancer	1.53e-05	0.000142	CcSEcCtD
Dasatinib—Erythema multiforme—Doxorubicin—kidney cancer	1.52e-05	0.000141	CcSEcCtD
Dasatinib—Pain—Capecitabine—kidney cancer	1.52e-05	0.000141	CcSEcCtD
Dasatinib—Constipation—Capecitabine—kidney cancer	1.52e-05	0.000141	CcSEcCtD
Dasatinib—Eye disorder—Doxorubicin—kidney cancer	1.5e-05	0.00014	CcSEcCtD
Dasatinib—Tinnitus—Doxorubicin—kidney cancer	1.5e-05	0.000139	CcSEcCtD
Dasatinib—Flushing—Doxorubicin—kidney cancer	1.49e-05	0.000139	CcSEcCtD
Dasatinib—Cardiac disorder—Doxorubicin—kidney cancer	1.49e-05	0.000139	CcSEcCtD
Dasatinib—Diarrhoea—Paclitaxel—kidney cancer	1.48e-05	0.000137	CcSEcCtD
Dasatinib—Feeling abnormal—Capecitabine—kidney cancer	1.46e-05	0.000136	CcSEcCtD
Dasatinib—Angiopathy—Doxorubicin—kidney cancer	1.46e-05	0.000136	CcSEcCtD
Dasatinib—Immune system disorder—Doxorubicin—kidney cancer	1.45e-05	0.000135	CcSEcCtD
Dasatinib—Gastrointestinal pain—Capecitabine—kidney cancer	1.45e-05	0.000135	CcSEcCtD
Dasatinib—Mediastinal disorder—Doxorubicin—kidney cancer	1.45e-05	0.000135	CcSEcCtD
Dasatinib—Chills—Doxorubicin—kidney cancer	1.44e-05	0.000134	CcSEcCtD
Dasatinib—Arrhythmia—Doxorubicin—kidney cancer	1.44e-05	0.000134	CcSEcCtD
Dasatinib—Dizziness—Paclitaxel—kidney cancer	1.43e-05	0.000133	CcSEcCtD
Dasatinib—Alopecia—Doxorubicin—kidney cancer	1.42e-05	0.000132	CcSEcCtD
Dasatinib—Mental disorder—Doxorubicin—kidney cancer	1.41e-05	0.000131	CcSEcCtD
Dasatinib—Urticaria—Capecitabine—kidney cancer	1.41e-05	0.000131	CcSEcCtD
Dasatinib—Body temperature increased—Capecitabine—kidney cancer	1.4e-05	0.00013	CcSEcCtD
Dasatinib—Abdominal pain—Capecitabine—kidney cancer	1.4e-05	0.00013	CcSEcCtD
Dasatinib—Erythema—Doxorubicin—kidney cancer	1.4e-05	0.00013	CcSEcCtD
Dasatinib—Malnutrition—Doxorubicin—kidney cancer	1.4e-05	0.00013	CcSEcCtD
Dasatinib—Vomiting—Paclitaxel—kidney cancer	1.37e-05	0.000128	CcSEcCtD
Dasatinib—Dysgeusia—Doxorubicin—kidney cancer	1.37e-05	0.000128	CcSEcCtD
Dasatinib—Rash—Paclitaxel—kidney cancer	1.36e-05	0.000127	CcSEcCtD
Dasatinib—Dermatitis—Paclitaxel—kidney cancer	1.36e-05	0.000127	CcSEcCtD
Dasatinib—Headache—Paclitaxel—kidney cancer	1.35e-05	0.000126	CcSEcCtD
Dasatinib—Muscle spasms—Doxorubicin—kidney cancer	1.35e-05	0.000125	CcSEcCtD
Dasatinib—Vision blurred—Doxorubicin—kidney cancer	1.32e-05	0.000123	CcSEcCtD
Dasatinib—Hypersensitivity—Capecitabine—kidney cancer	1.31e-05	0.000121	CcSEcCtD
Dasatinib—Ill-defined disorder—Doxorubicin—kidney cancer	1.3e-05	0.000121	CcSEcCtD
Dasatinib—Anaemia—Doxorubicin—kidney cancer	1.29e-05	0.00012	CcSEcCtD
Dasatinib—Nausea—Paclitaxel—kidney cancer	1.28e-05	0.000119	CcSEcCtD
Dasatinib—Asthenia—Capecitabine—kidney cancer	1.27e-05	0.000118	CcSEcCtD
Dasatinib—Malaise—Doxorubicin—kidney cancer	1.26e-05	0.000117	CcSEcCtD
Dasatinib—Vertigo—Doxorubicin—kidney cancer	1.26e-05	0.000117	CcSEcCtD
Dasatinib—Syncope—Doxorubicin—kidney cancer	1.26e-05	0.000117	CcSEcCtD
Dasatinib—Pruritus—Capecitabine—kidney cancer	1.25e-05	0.000117	CcSEcCtD
Dasatinib—Palpitations—Doxorubicin—kidney cancer	1.24e-05	0.000115	CcSEcCtD
Dasatinib—Loss of consciousness—Doxorubicin—kidney cancer	1.23e-05	0.000114	CcSEcCtD
Dasatinib—Cough—Doxorubicin—kidney cancer	1.22e-05	0.000114	CcSEcCtD
Dasatinib—Convulsion—Doxorubicin—kidney cancer	1.21e-05	0.000113	CcSEcCtD
Dasatinib—Diarrhoea—Capecitabine—kidney cancer	1.21e-05	0.000113	CcSEcCtD
Dasatinib—Hypertension—Doxorubicin—kidney cancer	1.21e-05	0.000112	CcSEcCtD
Dasatinib—Myalgia—Doxorubicin—kidney cancer	1.19e-05	0.000111	CcSEcCtD
Dasatinib—Arthralgia—Doxorubicin—kidney cancer	1.19e-05	0.000111	CcSEcCtD
Dasatinib—Chest pain—Doxorubicin—kidney cancer	1.19e-05	0.000111	CcSEcCtD
Dasatinib—Anxiety—Doxorubicin—kidney cancer	1.19e-05	0.00011	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	1.18e-05	0.00011	CcSEcCtD
Dasatinib—Discomfort—Doxorubicin—kidney cancer	1.18e-05	0.00011	CcSEcCtD
Dasatinib—Dizziness—Capecitabine—kidney cancer	1.17e-05	0.000109	CcSEcCtD
Dasatinib—Confusional state—Doxorubicin—kidney cancer	1.15e-05	0.000107	CcSEcCtD
Dasatinib—Oedema—Doxorubicin—kidney cancer	1.14e-05	0.000106	CcSEcCtD
Dasatinib—Infection—Doxorubicin—kidney cancer	1.13e-05	0.000106	CcSEcCtD
Dasatinib—Vomiting—Capecitabine—kidney cancer	1.13e-05	0.000105	CcSEcCtD
Dasatinib—Shock—Doxorubicin—kidney cancer	1.12e-05	0.000105	CcSEcCtD
Dasatinib—Nervous system disorder—Doxorubicin—kidney cancer	1.12e-05	0.000104	CcSEcCtD
Dasatinib—Thrombocytopenia—Doxorubicin—kidney cancer	1.12e-05	0.000104	CcSEcCtD
Dasatinib—Rash—Capecitabine—kidney cancer	1.12e-05	0.000104	CcSEcCtD
Dasatinib—Dermatitis—Capecitabine—kidney cancer	1.12e-05	0.000104	CcSEcCtD
Dasatinib—Tachycardia—Doxorubicin—kidney cancer	1.11e-05	0.000104	CcSEcCtD
Dasatinib—Headache—Capecitabine—kidney cancer	1.11e-05	0.000103	CcSEcCtD
Dasatinib—Skin disorder—Doxorubicin—kidney cancer	1.11e-05	0.000103	CcSEcCtD
Dasatinib—Hyperhidrosis—Doxorubicin—kidney cancer	1.1e-05	0.000103	CcSEcCtD
Dasatinib—Anorexia—Doxorubicin—kidney cancer	1.09e-05	0.000101	CcSEcCtD
Dasatinib—Hypotension—Doxorubicin—kidney cancer	1.07e-05	9.93e-05	CcSEcCtD
Dasatinib—Nausea—Capecitabine—kidney cancer	1.05e-05	9.79e-05	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Doxorubicin—kidney cancer	1.04e-05	9.68e-05	CcSEcCtD
Dasatinib—Insomnia—Doxorubicin—kidney cancer	1.03e-05	9.61e-05	CcSEcCtD
Dasatinib—Dyspnoea—Doxorubicin—kidney cancer	1.02e-05	9.48e-05	CcSEcCtD
Dasatinib—Somnolence—Doxorubicin—kidney cancer	1.02e-05	9.45e-05	CcSEcCtD
Dasatinib—Dyspepsia—Doxorubicin—kidney cancer	1.01e-05	9.36e-05	CcSEcCtD
Dasatinib—Decreased appetite—Doxorubicin—kidney cancer	9.93e-06	9.24e-05	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Doxorubicin—kidney cancer	9.86e-06	9.18e-05	CcSEcCtD
Dasatinib—Fatigue—Doxorubicin—kidney cancer	9.85e-06	9.16e-05	CcSEcCtD
Dasatinib—Constipation—Doxorubicin—kidney cancer	9.77e-06	9.09e-05	CcSEcCtD
Dasatinib—Pain—Doxorubicin—kidney cancer	9.77e-06	9.09e-05	CcSEcCtD
Dasatinib—Feeling abnormal—Doxorubicin—kidney cancer	9.41e-06	8.76e-05	CcSEcCtD
Dasatinib—Gastrointestinal pain—Doxorubicin—kidney cancer	9.34e-06	8.69e-05	CcSEcCtD
Dasatinib—Urticaria—Doxorubicin—kidney cancer	9.07e-06	8.44e-05	CcSEcCtD
Dasatinib—Abdominal pain—Doxorubicin—kidney cancer	9.03e-06	8.4e-05	CcSEcCtD
Dasatinib—Body temperature increased—Doxorubicin—kidney cancer	9.03e-06	8.4e-05	CcSEcCtD
Dasatinib—Hypersensitivity—Doxorubicin—kidney cancer	8.42e-06	7.83e-05	CcSEcCtD
Dasatinib—Asthenia—Doxorubicin—kidney cancer	8.2e-06	7.63e-05	CcSEcCtD
Dasatinib—Pruritus—Doxorubicin—kidney cancer	8.08e-06	7.52e-05	CcSEcCtD
Dasatinib—Diarrhoea—Doxorubicin—kidney cancer	7.82e-06	7.27e-05	CcSEcCtD
Dasatinib—Dizziness—Doxorubicin—kidney cancer	7.55e-06	7.03e-05	CcSEcCtD
Dasatinib—Vomiting—Doxorubicin—kidney cancer	7.26e-06	6.76e-05	CcSEcCtD
Dasatinib—Rash—Doxorubicin—kidney cancer	7.2e-06	6.7e-05	CcSEcCtD
Dasatinib—Dermatitis—Doxorubicin—kidney cancer	7.2e-06	6.7e-05	CcSEcCtD
Dasatinib—Headache—Doxorubicin—kidney cancer	7.16e-06	6.66e-05	CcSEcCtD
Dasatinib—Nausea—Doxorubicin—kidney cancer	6.79e-06	6.31e-05	CcSEcCtD
Dasatinib—PDGFRB—Signaling Pathways—MTOR—kidney cancer	4.9e-07	5.09e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—RELA—kidney cancer	4.9e-07	5.08e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—POMC—kidney cancer	4.89e-07	5.07e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—MAPK1—kidney cancer	4.88e-07	5.07e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CCND1—kidney cancer	4.87e-07	5.06e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—KRAS—kidney cancer	4.87e-07	5.05e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—ERBB2—kidney cancer	4.87e-07	5.05e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—JUN—kidney cancer	4.86e-07	5.05e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—PTEN—kidney cancer	4.86e-07	5.04e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—KRAS—kidney cancer	4.85e-07	5.04e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—MYC—kidney cancer	4.85e-07	5.03e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—RAF1—kidney cancer	4.84e-07	5.03e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—BRAF—kidney cancer	4.83e-07	5.01e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CTNNB1—kidney cancer	4.83e-07	5.01e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—RELA—kidney cancer	4.82e-07	5e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—JUN—kidney cancer	4.81e-07	5e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MTOR—kidney cancer	4.8e-07	4.98e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—ERBB2—kidney cancer	4.79e-07	4.97e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—CTNNB1—kidney cancer	4.78e-07	4.96e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MAPK3—kidney cancer	4.75e-07	4.93e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—MAPK1—kidney cancer	4.74e-07	4.92e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—PIK3CA—kidney cancer	4.74e-07	4.92e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—MAPK3—kidney cancer	4.74e-07	4.92e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—BCHE—kidney cancer	4.73e-07	4.91e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MTOR—kidney cancer	4.73e-07	4.91e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GSTP1—kidney cancer	4.72e-07	4.89e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PTEN—kidney cancer	4.7e-07	4.88e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—SLC5A5—kidney cancer	4.67e-07	4.85e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—KRAS—kidney cancer	4.67e-07	4.85e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—CDKN1B—kidney cancer	4.67e-07	4.85e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—RAF1—kidney cancer	4.66e-07	4.84e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—PTEN—kidney cancer	4.66e-07	4.83e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—KRAS—kidney cancer	4.65e-07	4.82e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—RELA—kidney cancer	4.64e-07	4.82e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—PIK3CA—kidney cancer	4.64e-07	4.82e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—PIK3CA—kidney cancer	4.64e-07	4.81e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MYC—kidney cancer	4.62e-07	4.8e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—PIK3CA—kidney cancer	4.62e-07	4.8e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—ERBB2—kidney cancer	4.61e-07	4.79e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—KRAS—kidney cancer	4.61e-07	4.79e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—MYC—kidney cancer	4.61e-07	4.78e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CDKN1B—kidney cancer	4.6e-07	4.78e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—RAF1—kidney cancer	4.6e-07	4.78e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ITPR2—kidney cancer	4.6e-07	4.77e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—RELA—kidney cancer	4.58e-07	4.76e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—ERBB2—kidney cancer	4.55e-07	4.73e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MTOR—kidney cancer	4.55e-07	4.72e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KIT—kidney cancer	4.55e-07	4.72e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—APC—kidney cancer	4.55e-07	4.72e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—PIK3CA—kidney cancer	4.53e-07	4.7e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MAPK1—kidney cancer	4.52e-07	4.7e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTGS2—kidney cancer	4.52e-07	4.69e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—SLC2A1—kidney cancer	4.51e-07	4.68e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—MAPK1—kidney cancer	4.51e-07	4.68e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—PIK3CA—kidney cancer	4.51e-07	4.68e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CDKN1B—kidney cancer	4.51e-07	4.68e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL2—kidney cancer	4.5e-07	4.67e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—MAPK3—kidney cancer	4.49e-07	4.66e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MTOR—kidney cancer	4.49e-07	4.66e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—VEGFA—kidney cancer	4.49e-07	4.66e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—kidney cancer	4.49e-07	4.66e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—KRAS—kidney cancer	4.48e-07	4.65e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—PIK3CA—kidney cancer	4.47e-07	4.64e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—PIK3CA—kidney cancer	4.46e-07	4.63e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CDKN1B—kidney cancer	4.44e-07	4.6e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—CTNNB1—kidney cancer	4.41e-07	4.58e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL2—kidney cancer	4.41e-07	4.58e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CCND1—kidney cancer	4.39e-07	4.56e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—JUN—kidney cancer	4.38e-07	4.55e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.38e-07	4.54e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CTNNB1—kidney cancer	4.35e-07	4.51e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL2—kidney cancer	4.34e-07	4.51e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GSTM1—kidney cancer	4.33e-07	4.5e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PTEN—kidney cancer	4.33e-07	4.49e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—POMC—kidney cancer	4.33e-07	4.49e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—kidney cancer	4.33e-07	4.49e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PTEN—kidney cancer	4.3e-07	4.46e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CCND1—kidney cancer	4.3e-07	4.46e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—PIK3CA—kidney cancer	4.29e-07	4.45e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—JUN—kidney cancer	4.29e-07	4.45e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—MAPK1—kidney cancer	4.28e-07	4.44e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—BRAF—kidney cancer	4.27e-07	4.44e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—KRAS—kidney cancer	4.27e-07	4.43e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CDKN1B—kidney cancer	4.27e-07	4.43e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—PIK3CA—kidney cancer	4.27e-07	4.43e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—KRAS—kidney cancer	4.26e-07	4.42e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CTNNB1—kidney cancer	4.26e-07	4.42e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—VEGFA—kidney cancer	4.25e-07	4.41e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MAPK3—kidney cancer	4.25e-07	4.41e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PTEN—kidney cancer	4.24e-07	4.4e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—PIK3CA—kidney cancer	4.24e-07	4.4e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CCND1—kidney cancer	4.23e-07	4.39e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.23e-07	4.38e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—JUN—kidney cancer	4.22e-07	4.38e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CDKN1B—kidney cancer	4.22e-07	4.38e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CTNNB1—kidney cancer	4.19e-07	4.35e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTT1—kidney cancer	4.19e-07	4.35e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ACHE—kidney cancer	4.19e-07	4.35e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL2—kidney cancer	4.18e-07	4.34e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—MAPK3—kidney cancer	4.15e-07	4.31e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PTEN—kidney cancer	4.15e-07	4.31e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MYC—kidney cancer	4.13e-07	4.29e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL2—kidney cancer	4.13e-07	4.28e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—PIK3CA—kidney cancer	4.12e-07	4.27e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CYP1A1—kidney cancer	4.11e-07	4.26e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PTEN—kidney cancer	4.09e-07	4.24e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CCND1—kidney cancer	4.08e-07	4.23e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—JUN—kidney cancer	4.07e-07	4.22e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—POMC—kidney cancer	4.06e-07	4.21e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MAPK1—kidney cancer	4.04e-07	4.19e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—KRAS—kidney cancer	4.04e-07	4.19e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—MYC—kidney cancer	4.04e-07	4.19e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CTNNB1—kidney cancer	4.04e-07	4.19e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—RAF1—kidney cancer	4.03e-07	4.18e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CCND1—kidney cancer	4.02e-07	4.18e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MAPK3—kidney cancer	4.02e-07	4.17e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—JUN—kidney cancer	4.01e-07	4.17e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—RELA—kidney cancer	4.01e-07	4.17e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ERBB2—kidney cancer	3.99e-07	4.14e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CTNNB1—kidney cancer	3.98e-07	4.13e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—MAPK3—kidney cancer	3.98e-07	4.13e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SCARB1—kidney cancer	3.97e-07	4.12e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—MAPK1—kidney cancer	3.95e-07	4.1e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTEN—kidney cancer	3.94e-07	4.09e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MTOR—kidney cancer	3.94e-07	4.08e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PTEN—kidney cancer	3.93e-07	4.08e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS1—kidney cancer	3.93e-07	4.08e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—PIK3CA—kidney cancer	3.93e-07	4.07e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—PIK3CA—kidney cancer	3.91e-07	4.06e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MYC—kidney cancer	3.91e-07	4.06e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PTEN—kidney cancer	3.88e-07	4.03e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PSMD7—kidney cancer	3.85e-07	4e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—POMC—kidney cancer	3.83e-07	3.98e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—kidney cancer	3.83e-07	3.97e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MAPK1—kidney cancer	3.82e-07	3.97e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.82e-07	3.96e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—KRAS—kidney cancer	3.82e-07	3.96e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—kidney cancer	3.8e-07	3.94e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—MAPK1—kidney cancer	3.79e-07	3.93e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTP1—kidney cancer	3.76e-07	3.91e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—kidney cancer	3.75e-07	3.89e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—KRAS—kidney cancer	3.73e-07	3.87e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—PIK3CA—kidney cancer	3.71e-07	3.85e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1B—kidney cancer	3.69e-07	3.83e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—kidney cancer	3.69e-07	3.83e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MAPK3—kidney cancer	3.67e-07	3.81e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—BCHE—kidney cancer	3.65e-07	3.79e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MAPK3—kidney cancer	3.62e-07	3.76e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL2—kidney cancer	3.61e-07	3.75e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KRAS—kidney cancer	3.61e-07	3.75e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SLC5A5—kidney cancer	3.61e-07	3.74e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—KRAS—kidney cancer	3.58e-07	3.71e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MYC—kidney cancer	3.57e-07	3.71e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—RAF1—kidney cancer	3.57e-07	3.7e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ABCB1—kidney cancer	3.56e-07	3.7e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—RELA—kidney cancer	3.55e-07	3.69e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—kidney cancer	3.55e-07	3.69e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MAPK3—kidney cancer	3.55e-07	3.68e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ERBB2—kidney cancer	3.53e-07	3.66e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCND1—kidney cancer	3.52e-07	3.66e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MYC—kidney cancer	3.52e-07	3.66e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—JUN—kidney cancer	3.52e-07	3.65e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—kidney cancer	3.51e-07	3.64e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PIK3CA—kidney cancer	3.51e-07	3.64e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MAPK1—kidney cancer	3.5e-07	3.63e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MAPK3—kidney cancer	3.49e-07	3.62e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CTNNB1—kidney cancer	3.49e-07	3.62e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MTOR—kidney cancer	3.48e-07	3.62e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SLC2A1—kidney cancer	3.48e-07	3.61e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTM1—kidney cancer	3.46e-07	3.59e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MYC—kidney cancer	3.45e-07	3.58e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MAPK1—kidney cancer	3.45e-07	3.58e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—PIK3CA—kidney cancer	3.43e-07	3.56e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PTEN—kidney cancer	3.4e-07	3.53e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MYC—kidney cancer	3.39e-07	3.52e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—kidney cancer	3.39e-07	3.52e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MAPK1—kidney cancer	3.37e-07	3.5e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MAPK3—kidney cancer	3.36e-07	3.49e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MAPK1—kidney cancer	3.32e-07	3.45e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PIK3CA—kidney cancer	3.32e-07	3.44e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MAPK3—kidney cancer	3.32e-07	3.44e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—KRAS—kidney cancer	3.3e-07	3.43e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—PIK3CA—kidney cancer	3.29e-07	3.41e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP1A1—kidney cancer	3.28e-07	3.4e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1B—kidney cancer	3.27e-07	3.39e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MYC—kidney cancer	3.27e-07	3.39e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KRAS—kidney cancer	3.25e-07	3.38e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTGS2—kidney cancer	3.24e-07	3.36e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MYC—kidney cancer	3.23e-07	3.35e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—kidney cancer	3.21e-07	3.33e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL2—kidney cancer	3.2e-07	3.32e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MAPK1—kidney cancer	3.2e-07	3.32e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KRAS—kidney cancer	3.19e-07	3.31e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MAPK1—kidney cancer	3.16e-07	3.28e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KRAS—kidney cancer	3.14e-07	3.26e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCND1—kidney cancer	3.12e-07	3.24e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—JUN—kidney cancer	3.11e-07	3.23e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CTNNB1—kidney cancer	3.09e-07	3.21e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—kidney cancer	3.07e-07	3.19e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—POMC—kidney cancer	3.06e-07	3.18e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTGS2—kidney cancer	3.06e-07	3.17e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PIK3CA—kidney cancer	3.06e-07	3.17e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PIK3CA—kidney cancer	3.03e-07	3.15e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KRAS—kidney cancer	3.02e-07	3.13e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PTEN—kidney cancer	3.01e-07	3.12e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PIK3CA—kidney cancer	2.99e-07	3.1e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KRAS—kidney cancer	2.98e-07	3.09e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PIK3CA—kidney cancer	2.93e-07	3.04e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAPK3—kidney cancer	2.91e-07	3.02e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTP1—kidney cancer	2.91e-07	3.01e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—kidney cancer	2.89e-07	3e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PIK3CA—kidney cancer	2.88e-07	2.99e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—kidney cancer	2.83e-07	2.94e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MYC—kidney cancer	2.83e-07	2.93e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTEN—kidney cancer	2.82e-07	2.93e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—kidney cancer	2.79e-07	2.89e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PIK3CA—kidney cancer	2.78e-07	2.88e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PIK3CA—kidney cancer	2.78e-07	2.88e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAPK1—kidney cancer	2.77e-07	2.87e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ABCB1—kidney cancer	2.75e-07	2.85e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PIK3CA—kidney cancer	2.74e-07	2.84e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—kidney cancer	2.72e-07	2.82e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.69e-07	2.8e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—kidney cancer	2.68e-07	2.79e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTM1—kidney cancer	2.67e-07	2.77e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTEN—kidney cancer	2.67e-07	2.77e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—kidney cancer	2.65e-07	2.75e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KRAS—kidney cancer	2.61e-07	2.71e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAPK3—kidney cancer	2.57e-07	2.67e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP1A1—kidney cancer	2.53e-07	2.63e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MYC—kidney cancer	2.5e-07	2.6e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAPK1—kidney cancer	2.45e-07	2.54e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—POMC—kidney cancer	2.45e-07	2.54e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTGS2—kidney cancer	2.44e-07	2.54e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CA—kidney cancer	2.4e-07	2.49e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—kidney cancer	2.32e-07	2.41e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KRAS—kidney cancer	2.31e-07	2.4e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTEN—kidney cancer	2.13e-07	2.21e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CA—kidney cancer	2.12e-07	2.2e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—kidney cancer	2.05e-07	2.13e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CA—kidney cancer	1.99e-07	2.07e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS2—kidney cancer	1.95e-07	2.02e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—POMC—kidney cancer	1.89e-07	1.96e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CA—kidney cancer	1.88e-07	1.95e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTEN—kidney cancer	1.7e-07	1.76e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS2—kidney cancer	1.51e-07	1.56e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CA—kidney cancer	1.5e-07	1.56e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTEN—kidney cancer	1.31e-07	1.36e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CA—kidney cancer	1.2e-07	1.25e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CA—kidney cancer	9.26e-08	9.61e-07	CbGpPWpGaD
